Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Some patients use maintenance protocols for ongoing digestive support
P.RodriguesC
D2P2 awards are typically reserved for companies that can demonstrate sufficient prior work or relevant experience to justify bypassing the feasibility stage
Andrea Corona MapLight reports mixed results in Schizophrenia trial In their Phase 2 ZEPHR trial, MapLights novel oral drug for schizophrenia, the Ml/M4 muscarinic agonist ML-007C-MA, successfully hit its primary endpoint but only for the twice-daily version, not the once-daily dose
US$ 25.56
US$ 21.42
US$ 27.81
US$ 22.82
US$ 22.13
